About Biodesix
Biodesix is a company based in Boulder (United States) founded in 2005. Biodesix has raised $200.16 million across 25 funding rounds from investors including Lincoln Park Capital. The company has 273 employees as of December 31, 2024. Biodesix has completed 2 acquisitions, including IndiDX and Xpresys Lung. Biodesix offers products and services including Diagnostic Tests and Development Services. Biodesix operates in a competitive market with competitors including Oncimmune, OncoCyte, Broncus, Riverain Tech and ONCOHOST, among others.
- Headquarter Boulder, United States
- Employees 273 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biodesix, Inc.
-
Annual Revenue
$71.32 M (USD)45.3as on Dec 31, 2024
-
Net Profit
-$42.93 M (USD)17.67as on Dec 31, 2024
-
EBITDA
-$28.8 M (USD)19.52as on Dec 31, 2024
-
Total Equity Funding
$200.16 M (USD)
in 25 rounds
-
Latest Funding Round
$40.3 M (USD), Post-IPO
Nov 23, 2022
- Investors
-
Employee Count
273
as on Dec 31, 2024
-
Investments & Acquisitions
IndiDX
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biodesix
Biodesix is a publicly listed company on the NASDAQ with ticker symbol BDSX in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biodesix
Biodesix offers a comprehensive portfolio of products and services, including Diagnostic Tests and Development Services.
Tests for lung cancer detection and personalized treatment guidance
Custom services for diagnostic tools and therapeutics development
People of Biodesix
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Software Development Team
11 people
Operations Team
6 people
Sales and Marketing
4 people
Business Team
3 people
Product Management Team
2 people
Human Resources and Administration
2 people
Customer Team
2 people
Unlock access to complete
Funding Insights of Biodesix
Biodesix has successfully raised a total of $200.16M across 25 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40.3 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biodesix
Biodesix has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Lincoln Park Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward North American opportunities.
|
Locked | Locked | Locked |
Investor details for Biodesix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biodesix
Biodesix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include IndiDX and Xpresys Lung.
Investment portfolio details for Biodesix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Proteomics-based liquid biopsy for lung cancer is provided.
|
Locked | Locked | 2013 | Locked | |
|
Blood-based diagnostics for oncology.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Biodesix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biodesix
Detailed financials for Biodesix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biodesix Comparisons
Peer comparison for Biodesix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biodesix
Biodesix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, OncoCyte, Broncus, Riverain Tech and ONCOHOST, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Minimally invasive technologies for lung disease treatment are developed.
|
|
| Locked | Locked | Locked |
Software tools are developed for early lung disease detection.
|
|
| Locked | Locked | Locked |
AI-based proteomic analysis for oncology therapy planning is offered.
|
Detailed competitors of Biodesix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biodesix
Complete news archive for Biodesix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biodesix
Biodesix was founded in 2005 and raised its 1st funding round 4 years after it was founded.
Biodesix is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Scott Hutton is the current CEO of Biodesix.
Biodesix is a funded company, having raised a total of $200.16M across 25 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Biodesix is 273.
Annual revenue of Biodesix is $71.32M as on Dec 31, 2024.
Biodesix was founded in 2005 and is headquartered in Boulder, United States. Diagnostic assays for cancer detection are developed by the company within the healthcare sector. In vitro diagnostic tests are provided, including Nodify Lung, which features two blood-based proteomic tests for assessing malignancy risk in lung nodules, and GeneStrat NGS for broad tumor mutation analysis. Operations focus on advancing precision medicine tools.
Biodesix offers Diagnostic Tests and Development Services.
Yes, Biodesix is publicly traded on NASDAQ under the ticker symbol BDSX.
Biodesix has made 2 acquisitions, including IndiDX, and Xpresys Lung.
Biodesix has 1 investor. Key investors include Lincoln Park Capital.
The ticker symbol of Biodesix is BDSX on NASDAQ.